5 November 2014
DETAILS
DSM well positioned …
• DSM significantly transformed
* Increased global reach; stronger presence
in High Growth Economies
* Capital allocation strongly focused on
Nutrition through targeted acquisitions
* Value creation through
sustainable innovation and new business platforms (EBAs)
* Pharma JVs established (DSP and DPx)
• Nutrition is a high quality business
* EBITDA margins of 20-23% with ~4% volume growth
* Delivering ~70% of Group EBITDA
• Performance Materials:
innovation driven, value-added businesses
* Improving EBITDA margins to 13-15%
* Set for leveraging our business/assets and
strong cash generation
… focusedondriving performance
• Focused strategy
* Improve operational performance of
the Nutrition and Performance Materials businesses
* Ongoing portfolio management:
strategic actions for
caprolactam, acrylonitrile and composite resins
* No large M&A contemplated for now:
current focus is on
integration of acquisitions of recent years
* Unlocking the value from
the developed innovation platforms
• Good shareholder return with ongoing commitment
to dividends Over €1bn in dividends paid since 2010
• Committed to long term shareholder value creation
WWW.CHEMWINFO.COM BY KHUN PHICHAI
